# Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

> **NCT04586088** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 58 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Chemotherapy Effect
- Immunotherapy
- Molecular Targeted Therapy

## Interventions

- **DRUG:** Apatinib plus Camrelizumab

## Key facts

- **NCT ID:** NCT04586088
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-05
- **Primary completion:** 2022-06-02
- **Final completion:** 2023-09-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04586088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04586088, "Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04586088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*